Related Experiment Videos
Idiopathic myelofibrosis: a retrospective study of 103 patients
Insights
Idiopathic myelofibrosis (IMF) patients experienced prolonged periods with minimal treatment, resulting in a low incidence of acute leukemia. However, major thromboembolic complications were observed, with a median survival of 4.3 years.
Area of Science:
- Hematology
- Oncology
- Clinical Medicine
Background:
- Idiopathic myelofibrosis (IMF) is a chronic myeloproliferative neoplasm.
- Characterized by bone marrow fibrosis, splenomegaly, and cytopenias.
Purpose of the Study:
- To retrospectively analyze the clinical course and survival of IMF patients.
- To evaluate the prognostic influence of various clinical parameters.
Main Methods:
- Retrospective analysis of 103 IMF patients diagnosed between 1967 and 1986.
- Data collected on symptoms, signs, treatment strategies, complications, and survival.
Main Results:
- Common findings included myelofibrosis (96%), splenomegaly (84%), and anemia (81%).
- A conservative treatment strategy led to a low incidence of acute leukemia (5%).
- Median survival was 4.3 years; no significant prognostic influence was found for age, sex, or laboratory parameters.
Conclusions:
- A conservative management approach for idiopathic myelofibrosis may be associated with a lower risk of acute leukemia.
- Several common clinical and laboratory parameters do not appear to significantly influence survival in IMF patients.
Abstract:
The clinical course of 103 patients (50 males, 53 females; median age 59 years) with idiopathic myelofibrosis (IMF) seen at our hospital between 1967 and 1986 was analyzed retrospectively. Common symptoms and signs at the time of diagnosis were: myelofibrosis (96%), splenomegaly (84%), anemia (81%), osteosclerosis (45%), malaise (41%) and leukocytosis (41%). It was possible to follow the majority of patients without treatment or with transfusion therapy only for prolonged periods of time. The use of cytostatic drugs and radiotherapy was restricted as much as possible. Probably due to this treatment strategy the incidence of acute leukemia was low (5%). Major thromboembolic complications were seen in 19% of the patients. Median survival of the patients was 4.3 years. The prognostic influence of several disease parameters determined at the time of diagnosis was tested: age, sex, leukocytes, platelets, hemoglobin, reticulocytes, LDH, ANP-score, spleen size and percentage of peripheral blood blasts + promyelocytes had no significant influence on the length of survival. Osteosclerosis, a presumed sign of advanced disease, was not correlated with survival either.